Generation of a homozygous TIGIT gene knockout (TIGIT−/−) human iPSC line (MUSIi001-A-3) using CRISPR/Cas9 system

IF 0.8 4区医学 Q4 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Stem cell research Pub Date : 2024-10-22 DOI:10.1016/j.scr.2024.103601

引用次数: 0

Abstract

Adoptive cell therapy for solid cancers involves enhancing and reinfusing immune cells to target tumor cells. The advancement of induced pluripotent stem cell technology enables the generation of immune cell products like T and NK cells for ACT. However, the expression of inhibitory receptors, such as TIGIT, may limit the functionality of these immune effector cells. In this study, we generated a homozygous TIGIT gene knockout iPSC line to potentially prevent inhibitory signaling and exhaustion, thereby creating potent “off-the-shelf” immune cell products for cellular immunotherapy applications. This approach could offer a new frontier in the fight against solid tumors.

查看原文本刊更多论文

利用 CRISPR/Cas9 系统生成同基因 TIGIT 基因敲除（TIGIT-/-）人 iPSC 株系（MUSIi001-A-3）。

针对实体瘤的适应性细胞疗法包括增强和再融合免疫细胞，以靶向肿瘤细胞。随着诱导多能干细胞技术的发展，T细胞和NK细胞等免疫细胞产品可用于ACT。然而，抑制性受体（如 TIGIT）的表达可能会限制这些免疫效应细胞的功能。在这项研究中，我们产生了一种同基因TIGIT基因敲除的iPSC细胞系，有可能防止抑制性信号传导和衰竭，从而为细胞免疫疗法应用创造出强效的 "现成 "免疫细胞产品。这种方法可以为抗击实体瘤提供一个新的领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Stem cell research 生物-生物工程与应用微生物

CiteScore

2.20

自引率

8.30%

发文量

338

审稿时长

55 days

期刊介绍： Stem Cell Research is dedicated to publishing high-quality manuscripts focusing on the biology and applications of stem cell research. Submissions to Stem Cell Research, may cover all aspects of stem cells, including embryonic stem cells, tissue-specific stem cells, cancer stem cells, developmental studies, stem cell genomes, and translational research. Stem Cell Research publishes 6 issues a year.